A number of agents have tocolytic effect, including β~2~-adrenergic receptor (β~2~-AR) agonists, magnesium sulfate, prostaglandin synthesis inhibitors, Ca^2+^-channel blockers, nitrogen monoxide donors, and oxytocin receptor antagonists ([@R1]). β~2~-AR agonists (such as salmeterol, terbutaline, fenoterol, hexoprenaline, and ritodrine) delay preterm labor for at least 48 hours, which is why they are the drugs of choice in the treatment of preterm labor ([@R2]). Of all tocolytics in use, β-mimetics have the most undesirable side-effect profile. The most serious reported side-effects associated with the administration of β~2~-AR agonists are pulmonary edema, hypotension, and tachycardia ([@R3],[@R4]). Promising new therapeutic approach for the treatment of preterm delivery is the combination β~2~-AR agonists and 17alpha-hydroxyprogesterone ([@R5]) or Ca^2+^-channel blocker nifedipine ([@R6]).

Adenosine triphosphate (ATP)-sensitive potassium channels (K~ATP~ channels) are involved in β-AR agonists-induced smooth muscle relaxation in pulmonary vasorelaxation in the rat ([@R7]), vasodilatation in the rat diaphragmatic microcirculation ([@R8]), vasorelaxation in the rat mesenteric artery ([@R9]), detrusor muscle relaxation in the rat ([@R10]), and myometrial relaxation in non-pregnant buffaloes ([@R11]). K~ATP~ channels are formed by a combination of two types of subunits, the pore-forming inwardly rectifying subunit (Kir~6x~) and the sulphonylurea-binding regulatory subunit (SUR) ([@R12]). We earlier reported ([@R13]) that SUR subunits, SUR1 and SUR2, are both expressed in the rat uterus during gestation. SUR1 expression was elevated in the early pregnancy (day 6) and then dramatically decreased from day 8 to term, while the level of SUR2 subunit remained unchanged.

The aim of the present study was to investigate the role of the K~ATP~ channel in β~2~-AR agonist-induced myometrial relaxation. We studied the tocolytic effects of β~2~-AR agonists (salmeterol, ritodrine) in the presence of glibenclamide (K~ATP~ channel blocker) and pinacidil (K~ATP~ channel opener) in early pregnant (day 6) and late pregnant (day 22) rats *in vitro*, in order to clarify the relation between SUR1 expression and pharmacological reactivity of β~2~-AR agonists.

Materials and methods
=====================

Mating of the animals
---------------------

The study was approved by the Hungarian Ethics Committee for Animal Research (registration number: IV/01758-2/2008) and the animals were treated in accordance with the European Communities Council Directives (86/609/ECC) and the Hungarian Act for the Protection of Animals in Research (XXVIII.tv.32.§). Sprague-Dawley rats (Charles-River Laboratories, Budapest, Hungary) were kept at 22 ± 3°C with relative humidity of 30%-70% and 12/12 h light/dark cycle. They were fed a standard rodent pellet diet (Charles-River Laboratories) with tap water available *ad libitum*.

Mature female (180-200 g) and male (240-260 g) rats were mated in a special mating cage with a metal door separating the rats of different sex, which is open when the rats are allowed to mate. Four to five hours after the potential mating, vaginal smears were taken from the female rats. The female rats in which sperm cells were microscopically detected (magnification of 1200 times) and those in whom smears could not have been taken because of a vaginal sperm plug were regarded as first-day pregnant animals ([@R13]).

Uterus preparation
------------------

The rats were euthanized by CO~2~ inhalation and the uteri were removed on the 6th and 22nd day of pregnancy. Muscle rings 5 mm long were sliced from the uterine horns and mounted vertically in an organ bath containing 10 mL of de Jongh solution (composition: 137 mM NaCl, 3 mM KCl, 1 mM CaCl~2~, 1 mM MgCl~2~, 12 mM NaHCO~3~, 4 mM NaH~2~PO~4~, 6 mM glucose, pH = 7.4). The organ bath was maintained at 37°C, and carbogen (95% O~2~ + 5% CO~2~) was bubbled through it. After mounting, the rings were equilibrated for about 1 h before the experiments, with a solution change every 15 min. The initial tension of the preparation was set to about 1.25 g, which was relaxed to about 0.5 g at the end of equilibration. The tension of the myometrial rings was measured with a gauge transducer (SG-02; Experimetria Ltd, Budapest, Hungary) and recorded with a SPEL Advanced ISOSYS Data Acquisition System (Experimetria Ltd) ([@R13]).

*In vitro* studies
------------------

The tissue samples were incubated for 5 min and the tocolytic effect of β~2~-AR agonists ritodrine and salmeterol (10^−10^-10^−5^ M) on spontaneous rhythmic contractions was investigated cumulatively, alone, or in the presence of K~ATP~ channel blocker glibenclamide (10^−6^ M) or K~ATP~ channel opener pinacidil (10^−9^-10^−7^ M). Following the addition of each dose of β~2~-AR agonist, the changes were recorded for 300 s. Concentration-response curves were fitted and areas under curves (AUCs) were determined. Statistical analysis was carried out with the Prism 5.0 (Graphpad Software Inc., San Diego, CA, USA). From the AUC values, maximum inhibitory effects (E~max~) of β~2~-AR agonists on a given day of pregnancy were calculated and the concentrations eliciting 50% of the maximum inhibition of uterine contraction (EC~50~) were calculated. Data were analyzed with the ANOVA Neuman-Keuls test. The alpha value was 0.05. The variances were constant and the distribution was normal.

Results
=======

Both glibenclamide and pinacidil influenced the effect of ritodrine and salmeterol
----------------------------------------------------------------------------------

Glibenclamide blocked the tocolytic effects of β~2~-AR agonists; the dose-response curves shifted to the right, and the EC~50~ values of β~2~-AR agonists significantly increased. Pinacidil enhanced the tocolytic effects of β~2~-AR agonists; the dose-response curves shifted to the left and the EC~50~ values of β~2~-AR agonists significantly decreased ([Figure 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![The tocolytic effect of β~2~-AR agonist salmeterol alone (10^−10^-10^−5^ M) (**S**) and in the presence of glibenclamide (S+G) and pinacidil (10^−9^ M: S+P9, 10^−8^ M: S+P8 and 10^−7^ M: S+P7) in the myometrium of 6-day-pregnant rat *in vitro* (mean± SE). The table shows EC~50~ data (mean ± SD, n = 6). Abbreviations: P9: pinacidil 10^−9^M, P8: pinacidil 10^−8^M, P7: pinacidil 10^−7^M, EC~50:~ the concentrations eliciting 50% of the maximum inhibitions of uterine contraction, SE: standard error, SD: standard deviation.](CroatMedJ_56_0114-F1){#F1}

![The tocolytic effect of β~2~-AR agonist ritodrine alone (10^−10^-10^−5^ M) (**R**) and in the presence of glibenclamide (R+G) and pinacidil (10^−9^ M: R+P9, 10^−8^ M: R+P8 and 10^−7^ M: R+P7) in the myometrium of 6-day-pregnant rat *in vitro* (mean± SE). The table shows EC~50~ data (mean ± SD, n = 6). See [Figure 1](#F1){ref-type="fig"} for abbreviations.](CroatMedJ_56_0114-F2){#F2}

Neither glibenclamide nor pinacidil influenced the effects of the β~2~-AR agonists on the 22 day pregnant uterus
----------------------------------------------------------------------------------------------------------------

The uterus-relaxant effects of ritodrine and salmeterol (10^−10^-10^−5^ M) on the 22-day-pregnant rat uterus were investigated in the presence of glibenclamide (10^−6^ M) or different doses of pinacidil (10^−9^, 10^−8^ and 10^−7^ M) ([Figure 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

![The tocolytic effect of β~2~-AR agonist salmeterol alone (10^−10^-10^−5^ M) (**S**), in the presence of glibenclamide (S+G), and pinacidil (10^−9^ M: S+P9, 10^−8^ M: S+P8 and 10^−7^ M: S+P7) in the myometrium of 22-day-pregnant rat *in vitro* (mean± SE). The table shows EC~50~ data (mean ±SD, n = 6). See [Figure 1](#F1){ref-type="fig"} for abbreviations.](CroatMedJ_56_0114-F3){#F3}

![The tocolytic effect of β~2~-AR agonist ritodrine (10^−10^-10^−5^ M) alone (**R**) in the presence of glibenclamide (R+G) and pinacidil (10^−9^ M: R+P9, 10^−8^ M: R+P8 and 10^−7^ M: R+P7) in the myometrium of 22-day-pregnant rat *in vitro* (mean± SE). The table shows EC~50~ data (mean ± SD, n = 6). See [Figure 1](#F1){ref-type="fig"} for abbreviations.](CroatMedJ_56_0114-F4){#F4}

Discussion
==========

Preterm delivery is one of the greatest challenges in obstetrical practice. The factors regulating myometrial function during pregnancy and labor are poorly understood. Understanding of these processes at cellular and molecular levels is essential for development of new therapeutic strategies. β~2~-ARs affect the contractility of the pregnant uterus which is why they are used for the treatment of premature labor.

K~ATP~ channels are large hetero-octameric complexes containing four subunits from the inwardly rectifying K^+^ channel family (Kir~6.x~: either Kir~6.1~ or Kir~6.2~) and four SUR subunits from the ABC transporter family: ABCC8 (SUR1) and ABCC9 (SUR2). SUR2 has two different isoforms, SUR2A and SUR2B, which are splicing variants. Both types of subunits, SURs and Kir~6.x~ are necessary for the channel function. Kir~6.x~ comprises the channel component of the K~ATP~, while the SURs are responsible for the ATP sensitivity, pharmacological properties, and trafficking of this channel ([@R14]-[@R18]). K~ATP~ channels have different molecular structure, due to the heterologous expression of the Kir~6.x~ and SUR subunits. This leads to different combinations and creates different types of K~ATP~ channels with distinct electrophysiological properties and pharmacological sensitivities.

We found earlier ([@R13]) that both SUR1 and SUR2 subunits were expressed in the rat uterus during gestation: SUR1 was markedly increased on day 6 and dramatically decreased from day 8 to term, while the level SUR2 subunit remained low during the entire gestation. The present study showed that K~ATP~ channels modulated the tocolytic effect of β~2~-AR agonists in the rat on day 6 of gestation. We clearly demonstrated that in the early gestation, when SUR1 level was elevated, tocolytic effect of β~2~-AR agonist was inhibited by glibenclamide and potentiated by pinacidil, while at the end of gestation, when SUR1 level was decreased, it was influenced by neither glibenclamide nor pinacidil. It can be concluded that the mediation effect of the K~ATP~ channels on the efficacy of the β~2~-AR agonist depends on the expression of the SUR1 subunit of the K~ATP~ channels. We had earlier demonstrated that the tocolytic effects of the β~2~-AR agonists in the rat significantly decreased in late (days 15, 18, 20, and 22 of gestation) compared to early gestation ([@R19]). This phenomenon could be explained by a decrease in the β~2~-AR function, which is partially controlled by β-adrenergic kinase, the estrogen/progesterone levels, and G-protein-coupled receptor kinases ([@R20]-[@R22]). Our results indicate that there are other mechanisms that decrease the tocolytic effect of β~2~-AR agonists at the end of gestation. The low levels of K~ATP~ channels at the end of gestation may facilitate the enhanced excitability and contractility of the myometrium, which is one of the reasons for the decreased efficacy of the betamimetics. It was shown ([@R23]) that SUR1 expression in the human myometrium was decreased in late pregnancy compared with non-pregnant women. Moreover, low levels of Kir~6.1~ and Kir~6.2~ subunits were determined at the end of gestation. Since open K~ATP~ channels draw the cell membrane potential closer to the K^+^ equilibrium potential, K~ATP~ channels are closely involved in reducing cellular excitability and contractility. The combination of betamimetics with a K~ATP~ channel opener will therefore not have any therapeutic relevance in the treatment of preterm birth. However, we can hypothesize that this combination may be used as a uterus relaxant in the early gestation (eg, habitual abortion).
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